Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis

Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis

Background: Sintilimab + a bevacizumab biosimilar (IBI305) (SB) and atezolizumab + bevacizumab (AB) have been approved for the treatment of unresectable hepatocellular carcinoma (HCC). At present, oncologists and their patients remain indecisive on their preferred treatment regime. Therefore, assess...

Full description

Bibliographic Details
Main Authors: Lu Li, Shilei Yang, Yanwei Chen, Li Tian, Ying He, Bin Wu, Deshi Dong
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Pharmacology
Subjects:
network meta-analysis
unresectable hepatocellular carcinoma
HCC
cost-effectiveness
immune checkpoint inhibitors plus an anti-VEGF antibody
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.891008/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.891008/full

Similar Items